首页> 美国政府科技报告 >Derived Intervention Levels for Tritium Based on Food and Drug Administration Methodology

【24h】

Derived Intervention Levels for Tritium Based on Food and Drug Administration Methodology

机译：基于食品药品管理方法的氚干预干预水平

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

In 1998, the FDA released it recommendations for age-dependent derived intervention levels for several radionuclides involved in nuclear accidents. One radionuclide that is not included in that document is tritium.

著录项

作者
Blanchard, A.;
展开▼
作者单位

展开▼
年度 1998
页码 1-15
总页数 15
原文格式 PDF
正文语种 eng
中图分类工业技术;
关键词
Tritium; Radiation doses; Nuclear accidents; Radionuclides;

机译：氚;辐射剂量;核事故;放射性核素;

相似文献

外文文献
中文文献
专利

1. Off-label antidepressant prescription in pediatric outpatients based on China Food and Drug Administration and Food and Drug Administration regulations: a Chinese retrospective study [J] . Deng Shuhua, Zhu Xiuqing, Sun Bin, International clinical psychopharmacology . 2018,第3期

机译：基于中国食品和药物管理和食品和药物管理局的小儿外留剂的抗抑郁药处方：中国回顾性研究
2. Four Food and Drug Administration Food and Drug Administration draft guidance documents and the REGROW Act REGROW Act : A litmus test for future changes in human cell‐ and tissue‐based products regulatory policy in the United States United States ? [J] . Yano Kazuo, Speidel Alessondra T., Yamato Masayuki Journal of tissue engineering and regenerative medicine . 2018,第7期

机译：四种食品和药物管理局食品和药物管理局指导文件和再生行为再生法案：用于未来的人类细胞和组织产品监管政策的Litmus测试，美国美国的监管政策？
3. American Epilepsy Society (AES): Written Comments to Norman E. "Ned" Sharpless, MD, Acting Commissioner of Food and Drugs, US Food and Drug Administration (FDA), Department of Health and Human Services (HHS) on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019 [J] . Welty Timothy E., Chapman Kevin E., Faught R. Edward Jr., Nature reviews Cancer . 2019,第6期

机译：美国癫痫社会（AES）：对Norman E.“Ned”的书面评论是“NED”Sharpless，MD，食品和药物代理人专员，美国食品和药物管理局（FDA），卫生和人类服务部（HHS）在Docket ID＃FDA -2019-n-1482，科学数据和有关包含大麻或大麻衍生化合物的产品的信息; 公开听证会; 申请评论：提交：2019年7月16日
4. Raising capital with uncertainty: Overpricing initial public offering for science-based firms with multiple ties to the food and drug administration [C] . Jay I. Chok Atlanta Conference on Science and Innovation Policy . 2009

机译：提高资本与不确定性：对食品和药物管理局的多个联系的基于科学公司的首次公开发布
5. Role of Patient Advocacy Stakeholders in Science-Based Regulatory Policy at the U.S. Food and Drug Administration (FDA) [D] . Kuehn, Carrie Melissa. 2017

机译：患者倡导利益相关者在美国食品和药物管理局（FDA）的科学研究政策中的作用
6. Food and Drug Administration Commentary on Methodological Issues in Negative Symptom Trials [O] . Thomas Laughren, Robert Levin 2011

机译：食品药品监督管理局对阴性症状试验中方法论问题的评论
7. Derived Intervention Levels for Tritium Based on Food and Drug Administration Methodology [O] . Blanchard, A. 1998

机译：基于食品药品管理方法的氚干预干预水平
8. Derived Intervention Levels for Tritium Based on Food and Drug Administration Methodology Using ICRP 56 Dose Coefficients [R] . Blanchard, A. 1999

机译：使用ICRp 56剂量系数基于食品和药物管理方法的氚干扰干预水平

Derived Intervention Levels for Tritium Based on Food and Drug Administration Methodology

摘要

著录项

相似文献

相关主题

期刊订阅